Polarean Imaging Plc (PLLWF)
OTC PINK OTC PINK Primary 
Polarean Imaging technology to be used in pharma-sponsored research programme
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has successfully expanded its new imaging service model by securing a deal to expand its Xenon MRI imaging platform into pharmaceutical research, marking a big step forward for the company. An unnamed leading global pharmaceutical firm has chosen Polarean's technology for a multicentre clinical trial, testing an investigational lung treatment.
Polarean Imaging beats revenue target
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) told investors it beat its revenue target for 2024, driven by the funding and strengthening undertaken during the year. The company today reported revenue of $3 million to $3.1 million for 2024, surpassing its previous guidance and more than tripling the $891,000 revenue reported in 2023.
Polarean tie-up provides evidence of widening horizons, though US remains core focus
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) on Monday showed evidence of a new strand of its sales and marketing strategy under its refreshed management team. Following the appointment of CEO Christopher von Jako in 2023, last year the company hired a new chief medical advisor and a new head of sales and marketing, after completing a $12.6 million financing round to accelerate the commercialization of its XENOVIEW medical imaging technology.
Polarean Imaging signs Taiwan agreement as first distribution deal
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has signed its first distribution agreement for its Xenon MRI platform, with a specialist medical distributor in Taiwan. The deal has been struck with Taiwan's Sumtage Enterprise Company Ltd, which has been introducing advanced medical equipment from overseas into its local market for the past 30 years.
Polarean Imaging chest coil receives FDA green light
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has received FDA 510(k) clearance for its XENOVIEW 3T chest coil to be used with GE HealthCare 3 Tesla (3T) MRI systems. The clearance allows the use of the device to support lung imaging using hyperpolarised Xenon-129 for oral inhalation in adults and children aged 12 and older.
Polarean Imaging's new sales VP explains his three-pronged strategy - ICYMI
Polarean Imaging PLC's (AIM:POLX, OTC:PLLWF) new Vice President of Sales, Alan Huang explains his background and plans to boost revenue. Alan Huang: My background has primarily been in MedTech imaging solutions for radiology and radiation oncology departments.
Polarean Imaging raises its revenue target
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF), a specialist in MRI imaging of the lungs, said it is raising its revenue guidance for the year to $2.5 million to $3 million after a strong first half. It posted sales of $1.1 million in the six months ended June 30, up from $100,000 in the same period last year.
Polarean Imaging appoints Xenon MRI specialist as its chief medical advisor
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has appointed Dr Chase Hall as chief medical advisor. An associate professor at the University of Kansas Medical Center, Hall specialises in pulmonary care and imaging biomarkers using Xenon MRI.
Polarean Imaging makes FDA supplemental submission to US FDA
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has submitted a New Drug Application supplement to the US Food & Drug Administration to allow XENOVIEW use in paediatric patients aged six years and older. The submission includes updates and new dose delivery bag sizes.
Polarean Imaging agrees trade-in deal with world-leading research centre
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) said it has agreed a trade-in deal with the University of Kansas Medical Center (KUMC) for a new clinical-grade Xenon MRI hyperpolariser system. KUMC, a leading academic centre in xenon MRI research, will exchange its existing hyperpolariser for the latest FDA-approved system provided by Polarean.
Polarean trade-in puts it on track for clinical base target, says Stifel
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) trade-in agreement to exchange the University of Virginia Health System's (UVA Health) existing two research hyperpolarisers for two new clinical-grade systems is an encouraging development, Stifel suggests. Further conversion of existing research polarisers into clinical grade units remains a key part of the commercial strategy to increase adoption of Xenon MRI in the US market, adds the broker.
Polarean Imaging inks deal to upgrade UVA equipment
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) announced on Friday an agreement with the University of Virginia Health System, which sees the upgrade of its equipment. It involves trading UVA Health's existing two research hyperpolarisers for two clinical-grade hyperpolariser systems provided by Polarean.
